NasdaqGS:MDGLBiotechs
Is Madrigal Pharmaceuticals (MDGL) Undervalued After Wider Losses In Its Second Quarter Results?
Madrigal Pharmaceuticals (MDGL) drew fresh attention on July 30, 2026, after reporting second quarter and six month results that showed wider net losses compared with the same periods a year earlier.
See our latest analysis for Madrigal Pharmaceuticals.
The latest results have coincided with pressure on Madrigal Pharmaceuticals' share price, which closed at $467.32 after falling 5.23% on the day and 14.18% over the past week. However, the 1 year total shareholder return of 54.65% points to...